Source: Annual Congress 2009 - Tuberculosis control
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
J. N. Kumar, K. K. Sharma, N. Jain, S. Jindal, M. Thakkar (Jaipur, India). Impact of drug resistance among new cases on outcome of DOTS category I. Eur Respir J 2009; 34: Suppl. 53, 2616

Member's Comments

No comment yet.

Related content which might interest you: Predicting outcomes and drug resistance with new standardised treatment Source: Eur Respir J 2011; 37: 974 Year: 2011 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002 Factors preventing better treatment completion among MDR TB cases in a rich-resource setting Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010 Outcome of drug resistant TB in hospital settings-a comparision of individualized treatment based on past history of anti-TB drugs with culture sensitivity guided treatment Source: Eur Respir J 2006; 28: Suppl. 50, 589s Year: 2006 Predicting outcomes and drug resistance with standardised treatment of active tuberculosis Source: Eur Respir J 2010; 36: 870-877 Year: 2010 Drug resistance in previously treated patients of tuberculosis in pre DOTS and DOTS era and its implications Source: Annual Congress 2009 - Tuberculosis control Year: 2009 MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009 DOTS program is associated with a reduction of multidrog resistant tuberculosis prevalence in new cases Source: Annual Congress 2003 - The various appearance of resistance Year: 2003 Drug resistance pattern of directly observed treatment shortcourse (DOTS) category-II relapse patients Source: Annual Congress 2011 - Tuberculosis epidemiology and public health Year: 2011 Could side effects of MDR-TB treatment change the outcome of the disease? Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 Frequency of side effects among patients with drug resistant tuberculosis (DR-TB) by resistance pattern in a high burden country. Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Treatment effectiveness and predictors of poor outcome in MDR-TB and XDR-TB Source: Breathe 2008; 6: 161 Year: 2009 Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Impact of social support programme on MDR-TB patients' treatment outcomes Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014 The impact of drug resistance on TB control and elimination Source: International Congress 2014 – New diagnostics and better treatments for multidrug and extensively drug-resistant tuberculosis (M/XDR-TB) Year: 2014